NIGHTINGALE HEALTH Aktie

 

Nightingale Health Plc, stock exchange release, 21 March 2025 at 1:00 p.m. (EET)   Nightingale Health Plc (“Nightingale Health” or the “Company”) announced on 17 March 2025 that the Company had submitted a request to OTC Markets Group Inc. (“OTC Markets”) for the admission of the Series B shares (the “Shares”) to trading on the OTCQX International market so that the first trading day would be on 19 March 2025, at the earliest, and 24 March 2025, at the latest. The Company confirms that trading in the B Shares and ADRs commences today, 21 March 2025, on the OTCQX International market....

NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced NIGHTINGALE HEALTH OYJ (Nasdaq Helsinki: HEALTH; OTCQX: NHLTY, NGHLF), a company focused on preventative healthcare, has qualified to trade on the OTCQX® Best Market....

Nightingale Health Plc Stock exchange release 18 March 2025 at 11:30 a.m. EET   Nasdaq Helsinki Ltd (“Nasdaq Helsinki”) has today approved the listing application of Nightingale Health Plc (“Nightingale Health” or the “Company”) to admit the Company's Series B shares (the “Shares”) to trading on the Main Market of Nasdaq Helsinki. Trading in the Shares commences on the Main Market of Nasdaq Helsinki on 19 March 2025, with the trading code HEALTH. The total number of Shares to be admitted to trading is 40,302,841 Shares.   Nightingale Health will transfer to the Main Market...

Nightingale Health Plc Stock exchange release 17 March 2025 at 4:15 p.m. EET   The Finnish Financial Supervisory Authority today approved Nightingale Health Plc's (“Nightingale Health” or the “Company”) Finnish-language prospectus (the “Finnish Prospectus”) in connection with the Company's transfer from the Nasdaq First North Growth Market Finland marketplace to the Main Market of Nasdaq Helsinki Ltd (“Nasdaq Helsinki”).   The Finnish Prospectus will be available on or about 17 March 2025 on Nightingale Health's website at https://ir.nightingalehealth.com/fi/...

Nightingale Health Plc Stock exchange release 17 March 2025 at 1:55 p.m. (EET)   Nightingale Health Plc (“Nightingale Health” or the “Company”) announced on 27 November 2024 that it was investigating the possibility of starting trading in the Company's Series B shares (the “Shares”) on the OTCQX International market managed by OTC Markets Group Inc. (“OTC Markets”) in the United States, with the aim of improving the liquidity of the Share and of achieving a broader international shareholder base. The Company has today submitted a request to OTC Markets for the admission of the...

Nightingale Health Plc Stock exchange release 12 March 2025 at 2:30 p.m. (EET) Nightingale Health Plc (“Nightingale Health” or the “Company”) has today submitted a listing application with Nasdaq Helsinki Ltd (“Nasdaq Helsinki”) to admit the Company's series B shares (the “Shares”) on trading on the Main Market of Nasdaq Helsinki (the “Listing”). The Listing is conditional upon Nasdaq Helsinki approving the Company's listing application and the Finnish Financial Supervisory Authority approving the prospectus prepared in connection with the Listing. Trading in the Shares is expected...

Nightingale Health Group's Half-year report 1 July 2024 – 31 December 2024 (unaudited)   Nightingale Health's half-year report: International expansion continues in Southeast Asia and the United States Company release, 6 March 2025 at 9:00 a.m. (EET)   This release is a summary of Nightingale Health Plc's Half-year report from period 1 July 2024 – 31 December 2024. The full Half-year report is attached to this release.   Numbers presented in brackets refer to corresponding year-on-year period unless otherwise stated. July-December 2024 key financials (IFRS)   -...